MediSieve's device captures Leukaemia blasts from the bloodstream in order to reduce the patient's white blood cell count.

Leukaemia is a cancer of the bone marrow where white blood cells (WBC) are produced. When a person has Leukaemia, the bone marrow produces a lot of abnormal and immature WBCs, or “blasts”, which multiply rapidly and are incapable of contributing to immune function.

These eventually spill over into the bloodstream crowding out normal cells. High levels of circulating Leukaemia blasts present problems for both chemotherapy and newer targeted monoclonal antibody therapies. The circulating cells can prevent the therapeutics from reaching the bone marrow where the disease begins and the death of large numbers of circulating cells can create potentially life-threatening side effects for the patient.

Significant worldwide burden

176k affected annually
1 death every 9 minutes

High morbidity and mortality

Mortality rate 35%

Stroke

Fatigue

Pneumonia

Heavy burden of patient care

Draining Chemotherapies

Constant blood tranfusions

long patient care

The long-term goal for clinical trials is to prove the value of magnetic filtration as a pre-treatment to traditional or next generation Leukaemia therapies. The MediSieve technology would only remove the blasts and would bring a patient's WBC count down to normal levels, reducing the side-effects of a further chemotherapy.

Latest News

MediSieve raises additional £1.8 million in funding

MediSieve raises additional £1.8 million in funding
June 24, 2021

MediSieve Ltd, a biotech company which has developed an innovative blood filtration device, today announced a £1.8m investment, led by 24Haymarket. This investment will fund first-inman trials investigating the safety and efficacy of the company’s pivotal IL-6 product. MediSieve has developed ...
Job Posting: Quality Manager

Job Posting: Quality Manager
May 05, 2021

Job Title: Quality Manager Reports to:  Head of Engineering and Quality Start Date:  July 2021 Hours of Work:  37.5 hours per week (full-time, 6-month probation) Salary:  £38-45k PA Please send your CV and a cover letter explaining what you can bring to MediSieve ...